Company news
Viridian Therapeutics, Inc. news in 2025
Viridian Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
December 21, 2025
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 4, 2025
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
November 2, 2025
Viridian Therapeutics Announces Proposed Underwritten Public Offering
October 20, 2025
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
October 20, 2025
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
October 19, 2025
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
September 14, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 5, 2025
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 29, 2025
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2025
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2025
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
May 19, 2025
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
May 6, 2025
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
May 5, 2025
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
April 6, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
January 7, 2025
Calls in 2025
Decks in 2025
- Investor Presentation (October 2025)
Investor deck · 56 slides · October 2025
- Investor Presentation (June 2025)
Investor deck · 56 slides · June 2025
- Technical Presentation (May 2025)
Technical · 14 slides · May 20, 2025